Incidence of Direct Oral Anticoagulant use in patients with non-valvular atrial fibrillation and characteristics of users in six European countries (2008-2015): A cross-national drug utilization study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Incidence of Direct Oral Anticoagulant use in patients with non-valvular atrial fibrillation and characteristics of users in six European countries (2008-2015) : A cross-national drug utilization study. / Ibáñez, L; Sabaté, M; Vidal, X; Ballarin, E; Rottenkolber, M; Schmiedl, S; Heeke, A; Huerta, C; Martin Merino, E; Montero, D; Leon-Muñoz, L M; Gasse, C; Moore, N; Droz, C; Lassalle, R; Aakjaer, M; Andersen, M; De Bruin, M L; Groenwold, R; van den Ham, R; Souverein, P; Klungel, O; Gardarsdottir, H.
I: British Journal of Clinical Pharmacology. Supplement, Bind 85, 2019, s. 2524-2539.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Incidence of Direct Oral Anticoagulant use in patients with non-valvular atrial fibrillation and characteristics of users in six European countries (2008-2015)
T2 - A cross-national drug utilization study
AU - Ibáñez, L
AU - Sabaté, M
AU - Vidal, X
AU - Ballarin, E
AU - Rottenkolber, M
AU - Schmiedl, S
AU - Heeke, A
AU - Huerta, C
AU - Martin Merino, E
AU - Montero, D
AU - Leon-Muñoz, L M
AU - Gasse, C
AU - Moore, N
AU - Droz, C
AU - Lassalle, R
AU - Aakjaer, M
AU - Andersen, M
AU - De Bruin, M L
AU - Groenwold, R
AU - van den Ham, R
AU - Souverein, P
AU - Klungel, O
AU - Gardarsdottir, H
N1 - This article is protected by copyright. All rights reserved.
PY - 2019
Y1 - 2019
N2 - AIMS: To estimate the incidence of Direct Oral Anticoagulant Drug (DOAC) use in patients with non-valvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries.METHODS: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed.RESULTS: A total of 186,405 new DOAC users (≥18 years) were identified. Standardized incidences varied from 1.93-2.60 and 0.11-8.71 users/10,000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10,000 (2012-2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10,000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only one database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP), and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany).CONCLUSION: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as co-morbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).
AB - AIMS: To estimate the incidence of Direct Oral Anticoagulant Drug (DOAC) use in patients with non-valvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries.METHODS: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed.RESULTS: A total of 186,405 new DOAC users (≥18 years) were identified. Standardized incidences varied from 1.93-2.60 and 0.11-8.71 users/10,000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10,000 (2012-2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10,000 inhabitants in SIDIAP (Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only one database includes the total reference population (DNR) while others are considered a population representative sample (CPRD, BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4% (SIDIAP), and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in AOK Nordwest (Germany).CONCLUSION: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There was variability in patient characteristics such as co-morbidities, potentially interacting drugs and dose adjustment. (EMA/2015/27/PH).
U2 - 10.1111/bcp.14071
DO - 10.1111/bcp.14071
M3 - Journal article
C2 - 31318059
VL - 85
SP - 2524
EP - 2539
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
SN - 0264-3774
ER -
ID: 226000066